Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.
Stocks · News reference
CRISPR Therapeutics Data From Its Phase 1 Clinical Study Of CTX Shows 79% Mean Reductions From Baseline For ANGPTL3, 48% Maximum For Triglycerides
CRISPR Therapeutics (NASDAQ:CRSP) today presented durability data from its Phase 1a clinical trial evaluating CTX310®, an investigational, in vivo CRISPR/Cas9 gene editing therapy targeting ANGPTL3. A single-course
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target
Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target